Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20094 in Overweight and Obese Subjects
NCT06839664Phase 3Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olatorepatide in Overweight and obesity (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Percent Change from Baseline in Body Weight at 48 weeks and Percentage of Participants Who Achieve weight loss >= 5% from Baseline at 48 weeks. Started Nov 2024; status: completed.
02
Drugs
olatorepatide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT06839664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839664.